This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


This week's roundup of Houston innovators includes Allie Danziger of Ampersand Professionals, Pete O'Heeron of Fibrobiologics, and Brandy Guidry of The Cannon. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health innovation to job training technology — recently making headlines in Houston innovation.

Allie Danziger, founder and CEO of Ampersand Professionals

After working with thousands of interns, Allie Danziger of Ampersand Professionals says she's now got a product to upskill and train new hires for employers. Photo courtesy of Ampersand

Allie Danziger is taking the workforce development programming she's created for training and matching interns with businesses to a whole new level. The new offering gives companies an opportunity to streamline their onboarding process with Ampersand's plug-and-play programming.

Danziger says usually new hires need the most experienced mentor or manager, but they don't usually get that support — especially when it comes to businesses that don't have their own built-out mentorship or training program.

"Ampersand’s new training product fills that gap — it gives employers of any size any easy solution to provide basic job readiness training to employees, access to our team of dedicated coaches, and a detailed report at the end of their training summarizing how their new hire did in the training and any trends recognized and tips for managing this employee based on what the platform uncovered," she says. "Businesses can also sign up for additional coaching sessions and customize training materials, as an add-on if interested." Click here to read more.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Fibroblasts have so much potential for a wide range of cell therapy treatments — the opportunities are endless, according to Pete O’Heeron, CEO, founder, and chairman of FiberBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FiberBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says on last week's episode of the Houston Innovators Podcast. "There's literally not biological process in the body where fibroblasts are not involved." Click here to listen to the episode and read more.

​Brandy Guidry, Pearland navigator at The Cannon

The Pearland Innovation Hub celebrates its launch this month. Photo via pearlandinnovationhub.com

The Pearland Economic Development Corp. has launched the Pearland Innovation Hub, aimed at connecting small businesses with programs and services that are designed to contribute to their success.

The Pearland Innovation Hub is managed through a partnership between the Pearland Economic Development Corp. and The Cannon, a Houston-area business networking community for entrepreneurs, investors, and corporate innovators. For now, the hub does not officially have a physical space. The Cannon hired Brandy Guidry to run the Pearland hub. She has more than 17 years of experience in business operations; engineering; technical marketing; innovation; and strategic planning, project, and program management.

“The Pearland Innovation Hub is a groundbreaking initiative to support existing and aspiring small business owners,” Guidry adds. Click here to read more.


Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Houston cell therapy company prepares to IPO, move into new facility

Houston Innovators Podcast episode 135

Stem cells have had their time in the spotlight for a while, and now it's time for fibroblasts to have their moment, according to Pete O’Heeron, CEO, founder, and chairman of FibroBiologics, a Houston-based company that’s using fibroblast cell technology to treat a variety of chronic diseases.

The two types of cells are the only ones that can be used in cell therapy for a regenerative treatment, meaning that specialists can take healthy stem cells and fibroblasts from a patient and inject them into a part of the body that needs it the most. And, according to O'Heeron and his team, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron on this week's Houston Innovators Podcast. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."

With over 150 patents issued or pending, O'Heeron's team has the most intellectual property surrounding fibroblasts in the world and, while there is a lot of activity in the stem cell space, they are the leader when it comes to fibroblasts, he says. FibroBiologics is the name of the entity O'Heeron is hoping to take public by the end of the year, but the business originated as SpinalCyte, specializing in spinal treatment, before evolving into FibroGenesis as the technology began treating more parts of the body.

"With fibroblasts being the most common cell in the human body, you have to assume its involved in every process of the human body," O'Heeron says. "There's literally not biological process in the body where fibroblasts are not involved."

The strongest treatments under FibroBiologics's umbrella are for degenerative disc disease, orthopedics, multiple sclerosis, and cancer. With these applications progressing, O'Heeron has imminent IPO plans for the company.

"We're in the process of getting the company public so that we can have access to the resources to do larger scale human trials. So, I think over the next year you'll see us launch at least two large scale human trials with fibroblast with the intention of submitting to the FDA for commercialization," O'Heeron says.

The company is in the process of building out a new 14,000-square-foot-space that will allow FibroBiologics to house its office, lab, and manufacturing space under one roof for the first time.

"These are fantastic robust cells, and we want to be able to control the quality and potency of them and how they ship out and how we're able to transfer those cells to the end user," O'Heeron says.

He shares more about the company and the impact he expects fibroblasts to have on cell therapy treatment. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


This innovative health care company has announced some big moves. Photo via Fibrobiologics.com

Houston health care company raises $100M and plans to IPO

big moves

A clinical stage therapeutic company has made some big moves — with an even bigger one on the horizon.

FibroBiologics, which is developing fibroblast-based therapeutic cures for chronic diseases, announced $100 million in fresh funding resulting from an agreement with GEM Global Yield LLC SCS, a private investment group, with offices in New York and Paris. The funds will be distributed over a 36-month term following a public listing of FibroBiologics common stock.

According to a news release, "FibroBiologics will control the timing and maximum amount of the drawdown under this facility and has no minimum drawdown obligation." The IPO could include acquisition via SPAC.

"This Agreement with GEM helps secure additional funding to further develop cell therapy cures in Multiple Sclerosis, Degenerative Disc Disease and Cancer using fibroblast cells," says Pete O'Heeron, CEO and chairman of FibroBiologics, in the release. "This Agreement provides for a strong balance sheet upon public listing and positions FibroBiologics for the next stage of commercial development to deliver life-changing abatement for patients with incurable chronic diseases."

Founded earlier this year, FibroBiologics offices in Southeast Houston adjacent to the University of Houston-Clear Lake campus, where O'Heeron completed his Masters in Healthcare Administration.

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston companies land on Deloitte’s Technology Fast 500 list

trending up

Three Houston companies have made this year’s Deloitte North America Technology Fast 500 list.

The report ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The Houston companies to make the list, along with their revenue growth rates from 2021-2024, include:

  • No. 16 Action1 Corp., a provider of cybersecurity software. Growth rate: 7,265 percent
  • No. 92 Cart.com, a commerce and logistics platform. Growth rate: 1,053 percent
  • No. 312 Tellihealth, a remote health care platform. Growth rate: 244 percent

“Houston’s unique blend of entrepreneurial energy and innovation continues to strengthen the local business community, and I’m thrilled to see Houston companies honored on the 2025 Deloitte Technology Fast 500 list. Congratulations to all the winners,” said Melinda Yee, managing partner in Deloitte’s Houston office.

Action1 is no stranger to lists like the Deloitte Technology Fast 500. For instance, the company ranked first among software companies and 29th overall on this year’s Inc. 5000, a list of the country’s fastest-growing private companies. Its growth rate from 2021 to 2024 reached 7,188 percent.

Mike Walters, president and co-founder of Action1, said in August that the Inc. 5000 achievement “reflects the dedication of Action1’s global team, who continue to execute against an ambitious vision: a world where cyberattacks exploiting vulnerabilities are entirely prevented across all types of devices, operating systems, and applications.”

Atlanta-based Impericus, operator of an AI-powered platform that connects health care providers with pharmaceutical and life sciences companies, topped the Deloitte list with a 2021-24 growth rate of 29,738 percent.

“Our mission is to set the standard for ethical AI-powered physician connections to pharma resources, accelerating and expanding patient access to needed treatments,” said Dr. Osama Hashmi, a dermatologist who’s co-founder and CEO of Impiricus. “As we continue to innovate quickly, we remain committed to building ethical bridges across this vital ecosystem.”

How executive education retains your best employees + drives success

Investing in People

Hiring is tough, but retaining great people is even harder. Ask almost any manager what keeps them up at night, and the answer usually comes back to the same thing: How do we keep our best employees growing here instead of looking elsewhere?

One reliable approach has held up across industries. When people see their employer investing in their development, they’re more likely to stay, contribute, and imagine a future with the organization.

The data backs this up. Employees who take part in ongoing training are far less likely to leave, and the effect is especially strong for younger workers. One national survey found that 86% of millennials would stay with an employer that invests in their development. Companies that build a real learning culture see retention jump by 30-50%. The pattern is consistent: When people can learn and advance, they stay.

The ROI of executive education
Professional development signals value, but it also builds capability. When people have access to structured learning, they become better problem-solvers, more adaptable, and more confident leading through change.

That's the focus of Executive Education at Rice University's Jones Graduate School of Business. The portfolio is built for the realities of modern leadership: AI and digital transformation courses for teams navigating new technologies, and deeper programs in innovation and strategy for leaders sharpening long-term thinking.

“People, managers, professionals, and executives in all functional areas of business can benefit from this program,” notes Jing Zhou, Mary Gibbs Jones Professor of Management and Psychology at Rice. “We teach the fundamental principles of how to drive innovation and broaden the cognitive space.”

That perspective runs through every offering, from the Rice Advanced Management Program to the Leadership Accelerator and Leading Innovation. Each program gives participants practical tools to think strategically, work across teams and make meaningful change inside their organizations.

Building the leadership pipeline
Leadership development isn’t a perk anymore. It’s a strategic need for any organization that wants to grow and stay competitive.

Employers know this — nearly two-thirds say leadership training is essential to their success — yet employees still report feeling stalled. Reports find 74% of employees feel they aren’t reaching their potential because they lacked meaningful growth opportunities.

Rice Business designs its Executive Education programs to address that gap. The Rice Advanced Management Program, for example, supports leaders preparing for C-suite, board, or enterprise-level roles. Its format — two in-person modules separated by several weeks — gives participants space to test ideas at work, return with questions, and build on what they’ve learned. The structure fits demanding executive schedules while creating room for deeper reflection and richer peer connections.

Just as important, the program helps senior leaders align on strategy and culture. Participants develop a shared language and build stronger relationships, which translates into clearer decision-making, better collaboration, and less burnout across teams.

Houston’s advantage
Houston gives Rice Business Executive Education a distinctive edge. The city’s position in energy, healthcare, logistics, and innovation means participants are learning in the middle of a global business ecosystem. That proximity brings a mix of perspectives you don’t get in more siloed markets, and it pushes leaders to apply ideas to real-world problems in real time.

The expertise runs deep on campus, as well. Participants learn from faculty who are shaping conversations in their fields, not just teaching from a playbook. For many organizations, that outside perspective is a meaningful complement to in-house training — a chance to stretch thinking, challenge assumptions, and broaden leadership capacity.

Rice Business offers multiple paths into that experience, from open-enrollment programs like Leading Organizational Change, Executive Leadership for Women, or Driving Growth through AI and Digital Transformation to fully customized corporate partnerships. Across all formats, the focus is the same: education that is practical, relevant, and built for impact.

Investing in retention and results
When organizations make room for real development, the payoff shows up quickly: higher engagement, stronger leadership pipelines, and lower turnover. It also shapes the culture. People are more willing to take risks, ask better questions, and stay curious when they know learning is part of the job.

As Brent Smith, senior associate dean for Executive Education at Rice Business, explains, “There’s a layer of learning in leadership that’s about helping people adopt a leadership identity — to see themselves as the actual leader for their organization. That’s not an easy transition, but it’s the foundation of lasting success.”

For companies that want to build loyalty, deepen leadership capacity, and stay competitive in a fast-changing environment, investing in people isn’t optional. Rice Business Executive Education offers a clear path to do it well. Learn more here.

Check out upcoming programs:

Houston’s 10 most valuable startups revealed in new report

by the numbers

The Greater Houston Partnership has released its list of the 10 most valuable startups that are fueling the city’s growth and entrepreneurial energy, including industry giants like Axiom Space and Fervo Energy.

Currently, Houston hosts more than 1,300 startups in industries such as energy, life sciences, manufacturing and aerospace, according to the GHP. The list ranks its top 10 startups by valuation based on the company’s last private funding round, reflected in Pitchbook data, as of Oct. 20 of this year.

The top 10 list includes:

10. NXTClean Fuels

Valuation: $530 million

NXTClean Fuels builds biofuel refineries that produce renewable fuel by using feedstocks like cooking oil and recycled organic materials.

9. Homebase

Valuation: $660 million

HR tech company Homebase provides employee management software that helps manage and optimize timesheets, payroll and more, with over over 100,000 small businesses and 2 million hourly workers using its product.

8. Zolve

Valuation: $800 million

Zolve is a banking platform that provides customers with access to financial products that aim to be accessible, flexible, and affordable than other financial platforms.

7. Stramsen Biotech

Valuation: $807 million

Stramsen Biotech develops plant-based drug therapies that target both infectious and noninfectious diseases, which include cancer, diabetes, HIV, kidney disease and neurological issues.

6. Octagos

Valuation: $843 million

Healthtech company Octagos has developed a remote cardiac monitoring software driven by AI that helps consolidate patient data in real-time, assisting healthcare professionals in providing quicker, easier and more accurate care.

5. Fervo Energy

Valuation: $1.4 billion

Pioneering geothermal company Fervo Energy combines horizontal drilling and fiber-optic sensing to produce electricity. The company is developing its flagship Cape Station geothermal power project in Utah. The first phase of the project will supply 100 megawatts of power beginning in 2026

4.Cart.com

Valuation: $1.7 billion

Cart.com is an e-commerce giant and logistics solutions provider that was founded in 2020 and obtained unicorn status within just three years.

3. Axiom Space

Valuation: $2.1 billion

Axiom Space is one of the anchor tenants at the Houston Spaceport, and has completed four missions of sending commercial astronauts to the ISS since 2022. In 2027, the company expects to see the first section of its private space station, Axiom Station, launched into low-earth orbit.

2. Solugen

Valuation: $2.175 billion

Solugen replaces petroleum-based products with plant-derived substitutes through its Bioforge manufacturing platform.

1. HighRadius

Valuation: $3.2 billion

HighRadius uses advanced technology to automate and manage accounts receivable processes for businesses worldwide.

The GHP also released its State of Houston’s Tech and Innovation Landscape, which mapped Houston’s digital and innovation sectors. Read the full report here.